The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review
Abstract
IMPORTANCE: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are related inflammatory disorders occurring in persons aged 50 years and older. Diagnostic and therapeutic approaches are heterogeneous in clinical practice. OBJECTIVE: To summarize current evidence regarding optimal methods for diagnosing and treating PMR and GCA. EVIDENCE REVIEW: MEDLINE, EMBASE, and Cochrane databases were searched from their inception dates to March 30, 2016. Screening by 2 authors resulted in 6626 abstracts, of which 50 articles met the inclusion criteria. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool or American College of Cardiology Foundation/American Heart Association methodology. FINDINGS: Twenty randomized clinical trials for therapy (n = 1016 participants) and 30 imaging studies for diagnosis and/or assessing response to therapy (n = 2080 participants) were included. The diagnosis of PMR is based on clinical features such as new-onset bilateral shoulder pain, including subdeltoid bursitis, muscle or joint stiffness, and functional impairment. Headache and visual disturbances including loss of vision are characteristic of GCA. Constitutional symptoms and elevated inflammatory markers (>90%) are common in both diseases. Ultrasound imaging enables detection of bilateral subdeltoid bursitis in 69% of PMR patients. In GCA, temporal artery biopsy remains the standard for definitive diagnosis. Ultrasound and magnetic resonance imaging (MRI) of large vessels revealing inflammation-induced wall thickening support the diagnosis of GCA (specificity 78%-100% for ultrasound and 73%-97% for MRI). Glucocorticoids remain the primary treatment, but the optimal initial dose and tapering treatment regimens are unknown. According to consensus-based recommendations, initial therapy for PMR is prednisone, 12.5 to 25 mg/day or equivalent, and 40 to 60 mg/day for GCA, followed by individualized tapering regimens in both diseases. Adjunctive methotrexate may reduce cumulative glucocorticoid dosage by 20% to 44% and relapses by 36% to 54% in both PMR and GCA. Use of tocilizumab as additional treatment with prednisone showed a 2- to 4-fold increase in remission rates of GCA in a randomized clinical trial (N = 30). CONCLUSIONS AND RELEVANCE: Diagnosis of PMR/GCA is made by clinical features and elevated inflammatory markers. In PMR, ultrasound imaging may improve diagnostic accuracy. In GCA, temporal artery biopsy may not be required in patients with typical disease features accompanied by characteristic ultrasound or MRI findings. Consensus-based recommendations suggest glucocorticoids as the most effective therapy for PMR/GCA. Methotrexate may be added to glucocorticoids in patients at risk for relapse and in those with glucocorticoid-related adverse effects or need for prolonged glucocorticoid therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies
Whiting, P. F., Rutjes, A. W. S., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M. G., Sterne, J. A. C., Bossuyt, P. M. M., & the QUADAS-2 Group* (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00009 · Cited by 14,199
Lawrence, R. C., Felson, D. T., Helmick, C. G., Arnold, L. M., Choi, H., Deyo, R. A., Gabriel, S., Hirsch, R., Hochberg, M. C., Hunder, G. G., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23176 · Cited by 5,499
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
Hunder, G. G., Bloch, D. A., Michel, B. A., Stevens, M. B., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., Lie, J. T., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330810 · Cited by 2,539
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Andrews, J., Guyatt, G., Oxman, A. D., Alderson, P., Dahm, P., Falck-Ytter, Y., Nasser, M., Meerpohl, J., Post, P. N., Kunz, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.03.013 · Cited by 1,416
Andrews, J. C., Schünemann, H. J., Oxman, A. D., Pottie, K., Meerpohl, J. J., Coello, P. A., Rind, D., Montori, V. M., Brito, J. P., Norris, S., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.003 · Cited by 1,315
Medium- and Large-Vessel Vasculitis
Weyand, C. M., & Goronzy, J. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmra022694 · Cited by 788
EULAR recommendations for the management of large vessel vasculitis
Mukhtyar, C. B., Guillevin, L., Cid, M. C., Dasgupta, B., de Groot, K., Gross, W. L., Hauser, T., Hellmich, B., Jayne, D. R. W., Kallenberg, C. G. M., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.088351 · Cited by 673
Self-citationDasgupta, B., Cimmino, M. A., Maradit-Kremers, H., Schmidt, W. A., Schirmer, M., Salvarani, C., Bachta, A., Dejaco, C., Duftner, C., Jensen, H. S., et al. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200329 · Cited by 673
Self-citationCrowson, C. S., Matteson, E. L., Myasoedova, E., Michet, C. J., Ernste, F. C., Warrington, K. J., Davis, J. M., Hunder, G. G., Therneau, T. M., & Gabriel, S. E. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30155 · Cited by 638
Self-citationBlockmans, D., Ceuninck, L. D., Vanderschueren, S., Knockaert, D., Mortelmans, L., & Bobbaers, H. (2006) · Arthritis Care & Research · doi:10.1002/art.21699 · Cited by 628
Mahr, A. D., Jover, J. A., Spiera, R. F., Hernández‐García, C., Fernández‐Gutiérrez, B., LaValley, M. P., & Merkel, P. A. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22754 · Cited by 622
Hoffman, G. S., Cid, M. C., Hellmann, D. B., Guillevin, L., Stone, J. H., Schousboe, J., Cohen, P., Calabrese, L. H., Dickler, H., Merkel, P. A., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10262 · Cited by 579
Villiger, P. M., Adler, S., Kuchen, S., Wermelinger, F., Dan, D., Fiege, V., Bütikofer, L., Seitz, M., & Reichenbach, S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00560-2 · Cited by 577
Hoffman, G. S., Cid, M. C., Rendt-Zagar, K. E., Merkel, P. A., Weyand, C. M., Stone, J. H., Salvarani, C., Xu, W., Visvanathan, S., Rahman, M. U., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00004 · Cited by 563
Jover, J. A., Hernández-García, C., Morado, I. C., Vargas, E., Bañares, A., & Fernández-Gutiérrez, B. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00010 · Cited by 518
An evaluation of criteria for polymyalgia rheumatica.
Bird, H. A., Esselinckx, W., Dixon, A. S., Mowat, A. G., & Wood, P. H. (1979) · Annals of the Rheumatic Diseases · doi:10.1136/ard.38.5.434 · Cited by 490
BSR and BHPR guidelines for the management of giant cell arteritis
Dasgupta, B., Borg, F. A., Hassan, N., Alexander, L., Barraclough, K., Bourke, B., Fulcher, J., Hollywood, J., Hutchings, A., James, P., et al. (2010) · Rheumatology · doi:10.1093/rheumatology/keq039a · Cited by 444
Self-citationHUSKISSON, E. C., & HART, F. D. (1987) · Joint Disease · doi:10.1016/b978-0-7236-0571-3.50187-7 · Cited by 436
Giant-Cell Arteritis and Polymyalgia Rheumatica
Weyand, C. M., & Goronzy, J. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmcp1214825 · Cited by 410
Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.
De Silva, M., & Hazleman, B. L. (1986) · Annals of the Rheumatic Diseases · doi:10.1136/ard.45.2.136 · Cited by 360
Mazlumzadeh, M., Hunder, G. G., Easley, K. A., Calamia, K. T., Matteson, E. L., Griffing, W. L., Younge, B. R., Weyand, C. M., & Goronzy, J. J. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22163 · Cited by 347
Self-citationBlockmans, D., Stroobants, S., Maes, A., & Mortelmans, L. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00424-6 · Cited by 347
Salvarani, C., Gabriel, S. E., O'Fallon, W. M., & Hunder, G. G. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-3-199508010-00006 · Cited by 344
Giant Cell Arteritis: Disease Patterns of Clinical Presentation in a Series of 240 Patients
Gonzalez-Gay, M. A., Barros, S., Lopez-Diaz, M. J., Garcia-Porrua, C., Sanchez-Andrade, A., & Llorca, J. (2005) · Medicine · doi:10.1097/01.md.0000180042.42156.d1 · Cited by 322
Dejaco, C., Singh, Y. P., Perel, P., Hutchings, A., Camellino, D., Mackie, S., Abril, A., Bachta, A., Balint, P., Barraclough, K., et al. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39333 · Cited by 312
Self-citationLong-term follow-up of polymyalgia rheumatica: Evidence for synovitis
Healey, L. A. (1984) · Seminars in Arthritis and Rheumatism · doi:10.1016/0049-0172(84)90012-x · Cited by 307
Smeeth, L., Cook, C., & Hall, A. J. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.046912 · Cited by 299
Skip Lesions in Temporal Arteritis
Klein, R. G., Campbell, R. J., Hunder, G. G., & Carney, J. A. (1976) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(25)05173-0 · Cited by 285
Salvarani, C., Cimino, L., Macchioni, P., Consonni, D., Cantini, F., Bajocchi, G., Pipitone, N., Catanoso, M. G., & Boiardi, L. (2005) · Arthritis Care & Research · doi:10.1002/art.21075 · Cited by 284
Blockmans, D., De Ceuninck, L., Vanderschueren, S., Knockaert, D., Mortelmans, L., & Bobbaers, H. (2006) · Rheumatology · doi:10.1093/rheumatology/kel376 · Cited by 281
Prognosis and management of polymyalgia rheumatica.
Jones, J. G., & Hazleman, B. L. (1981) · Annals of the Rheumatic Diseases · doi:10.1136/ard.40.1.1 · Cited by 276
Caporali, R., Cimmino, M. A., Ferraccioli, G., Gerli, R., Klersy, C., Salvarani, C., Montecucco, C., & for the Systemic Vasculitis Study Group of the Italian Society for Rheumatology (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-7-200410050-00005 · Cited by 261
Seror, R., Baron, G., Hachulla, E., Debandt, M., Larroche, C., Puéchal, X., Maurier, F., de Wazieres, B., Quéméneur, T., Ravaud, P., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203586 · Cited by 256
BSR and BHPR guidelines for the management of polymyalgia rheumatica
Dasgupta, B., Borg, F. A., Hassan, N., Barraclough, K., Bourke, B., Fulcher, J., Hollywood, J., Hutchings, A., Kyle, V., Nott, J., et al. (2010) · Rheumatology · doi:10.1093/rheumatology/kep303a · Cited by 251
Self-citationThe epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica
Bengtsson, B., & Malmvall, B. (1981) · Arthritis & Rheumatism · doi:10.1002/art.1780240706 · Cited by 250
van der Veen, M. J., Dinant, H. J., van Booma-Frankfort, C., van Albada-Kuipers, G. A., & Bijlsma, J. W. (1996) · Annals of the Rheumatic Diseases · doi:10.1136/ard.55.4.218 · Cited by 212
Epidemiology of polymyalgia rheumatica in olmsted county, minnesota, 1970–1991
Salvarani, C., Gabriel, S. E., Michael O'Fallon, W., & Hunder, G. G. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380311 · Cited by 208
Salvarani, C., Macchioni, P., Manzini, C., Paolazzi, G., Trotta, A., Manganelli, P., Cimmino, M., Gerli, R., Catanoso, M. G., Boiardi, L., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-9-200705010-00005 · Cited by 199
Is Duplex Ultrasonography Useful for the Diagnosis of Giant-Cell Arteritis?
Salvarani, C., Silingardi, M., Ghirarduzzi, A., Lo Scocco, G., Macchioni, P., Bajocchi, G., Vinceti, M., Cantini, F., Iori, I., & Boiardi, L. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-4-200208200-00006 · Cited by 195
Chevalet, P., Barrier, J., Pottier, P., Magadur-Joly, G., Pottier, M., Hamidou, M. A., Planchon, B., Kouri, D. E., Connan, L., Dupond, J. L., et al. (2000) · PubMed · Cited by 193
Klink, T., Geiger, J., Both, M., Ness, T., Heinzelmann, S., Reinhard, M., Holl-Ulrich, K., Duwendag, D., Vaith, P., & Bley, T. A. (2014) · Radiology · doi:10.1148/radiol.14140056 · Cited by 190
Carmona, F. D., Mackie, S. L., Martín, J.-E., Taylor, J. C., Vaglio, A., Eyre, S., Bossini-Castillo, L., Castañeda, S., Cid, M. C., Hernández-Rodríguez, J., et al. (2015) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2015.02.009 · Cited by 176
Self-citationACCF/AHA Clinical Practice Guideline Methodology Summit Report
Jacobs, A. K., Kushner, F. G., Ettinger, S. M., Guyton, R. A., Anderson, J. L., Ohman, E. M., Albert, N. M., Antman, E. M., Arnett, D. K., Bertolet, M., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.025 · Cited by 175
Bley, T. A., Weiben, O., Uhl, M., Vaith, P., Schmidt, D., Warnatz, K., & Langer, M. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21226 · Cited by 154
Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis.
Aschwanden, M., Imfeld, S., Staub, D., Baldi, T., Walker, U. A., Berger, C. T., Hess, C., & Daikeler, T. D. (2015) · PubMed · Cited by 153
Kyle, V., & Hazleman, B. L. (1989) · Annals of the Rheumatic Diseases · doi:10.1136/ard.48.8.658 · Cited by 151
Franzen, P., Sutinen, S., & von Knorring, J. (1992) · PubMed · Cited by 123
Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study.
Ferraccioli, G., Salaffi, F., Vita, S. D., et al. (1996) · PubMed · Cited by 116
Doran, M. F., Crowson, C. S., O’Fallon, W. M., Hunder, G. G., & Gabriel, S. E. (2002) · PubMed · Cited by 115
Dasgupta, B., Dolan, A. L., Panayi, G. S., et al. (1998) · Lara D. Veeken · doi:10.1093/rheumatology/37.2.189 · Cited by 112
Self-citationEffect of etanercept in polymyalgia rheumatica: a randomized controlled trial
Kreiner, F. F., & Galbo, H. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3140 · Cited by 102
Habib, H. M., Essa, A. A., & Hassan, A. A. (2011) · Clinical Rheumatology · doi:10.1007/s10067-011-1808-0 · Cited by 70
Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica
Dolan, A. L., Moniz, C. F., Li, F., Mackintosh, C., Todd, P., Dasgupta, B., Corrigall, V., & Panayi, G. S. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401115 · Cited by 62
Self-citation
Cited by
Cardiovascular toxicities associated with immune checkpoint inhibitors
Hu, J.-R., Florido, R., Lipson, E. J., Naidoo, J., Ardehali, R., Tocchetti, C. G., Lyon, A. R., Padera, R. F., Johnson, D. B., & Moslehi, J. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz026 · Cited by 508
Glucocorticoids—All-Rounders Tackling the Versatile Players of the Immune System
Strehl, C., Ehlers, L., Gaber, T., & Buttgereit, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01744 · Cited by 308
Self-citationDuftner, C., Dejaco, C., Sepriano, A., Falzon, L., Schmidt, W. A., & Ramiro, S. (2018) · RMD Open · doi:10.1136/rmdopen-2017-000612 · Cited by 302
Self-citationBurmester, G. R., Buttgereit, F., Bernasconi, C., Álvaro-Gracia, J. M., Castro, N., Dougados, M., Gabay, C., van Laar, J. M., Nebesky, J. M., Pethoe-Schramm, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30636-x · Cited by 128
Self-citation
Metadata
- Authors
- Buttgereit, F., Dejaco, C., Matteson, E. L., & Dasgupta, B.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-06-14
- Volume
- 315
- Issue
- 22
- Pages
- 2442
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2427523709
- Cited by
- 496
- References
- 55
- FWCI
- 42.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.